Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure

Leukemia

Volumn 15, Issue 4, 2001, Pages 559-566

  Radosevic, N ^a   Delmer, A ^a   Tang, R ^a   Marie, J P ^a   Ajchenbaum Cymbalista, F ^a  

^a HÔTEL DIEU   (France)

Author keywords

Acute myeloid leukemia; Cell cycle; Cytosine arabinoside; Daunorubicin

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; PROTEIN P21; PROTEIN P27; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MITOSIS INHIBITION; MONOCYTE; PHOSPHORYLATION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SAMPLE; SERUM; TIME;

EID: 85047695117     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402092     Document Type: Article

References (56)

1. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases
2. CDK inhibitors: Positive and negative regulators of G1-phase progression
3. Molecular interaction map of the mammalian cell cycle control and DNA repair systems
4. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1)
5. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia
6. Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells
7. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia
8. The role of decreased retinoblastoma protein expression in acute myelomonocytic and monoblastic leukemias
9. The retinoblastoma gene (rb1) in acute myeloid leukaemia: Analysis of gene rearrangements, protein expression and comparison of disease outcome
10. Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells
11. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: A prospective study
12. Expression of different conformations of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics
13. Overexpression of cyclin E in acute myelogenous leukemia
14. Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia
15. The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro
16. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents
17. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
18. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
19. Saturation of 1-beta-D-arabinofuranosyl-cytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy
20. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group
21. Quantitation of resistance of leukemic cells to cytosine arabinoside from BrdUrd/DNA bivariate histograms
22. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
23. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia
24. Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias
25. Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cells
26. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia
27. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias
28. P53 gene mutations in acute myelogenous leukaemia
29. Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level
30. The predominant E2F complex in human primary haemopoietic cells and in AML blasts contains E2F-4, DP-1 and p130
31. Deletion of the human retinoblastoma gene in primary leukemias
32. Altered expression of the human retinoblastoma gene in monocytic leukaemias
33. Cyclin D1 is a nuclear protein required for cell cycle progression in G1
34. Expression of G1-phase cell cycle genes during hematopoietic lineage
35. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein
36. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
37. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-Prognostic implications
38. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
39. Deregulated expression of p27(Kip1) in human breast cancers
40. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer
41. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints
42. DNA damage and cell cycle checkpoints
43. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents
44. G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells
45. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation
46. Lethal effects of 1-beta-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair
47. Biochemical and cellular pharmacology of cytosine arabinoside
48. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60)
49. Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines
50. Activation of cyclin E-dependent kinase by DNA-damage signals during apoptosis
51. Caspase-dependent Cdk activity is a requisite effector of apoptotic death events
52. CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside
53. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex
54. Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells
55. P53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage
56. Uncoupling of p21WAF1/CIP1/SDI1 mRNA and protein expression upon genotoxic stress